NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

Kemas kini terakhir: 2 jam lalu

67.26

-0.98 (-1.44%)

  • 1H -1.44%
  • 5H -4.14%
  • 1B -24.74%
  • 6B -41.56%
  • Tahun Ke Tarikh -23.15%
  • 1T -47.04%
  • 5T 124.79%
Penutupan Terdahulu 68.24
Buka 68.43
Jumlah Dagangan 7,782,861
Purata Dagangan (3B) 8,518,036
Modal Pasaran 295,322,943,488
Harga / Pendapatan (P/E TTM) 20.51
Harga / Pendapatan (P/E Ke hadapan) 19.01
Harga / Jualan (P/S) 8.08
Harga / Buku (P/B) 16.26
Julat 52 Minggu
66.88 (-0%) — 148.15 (120%)
Tarikh Pendapatan 7 May 2025
Hasil Dividen (DY TTM) 2.40%
Margin Keuntungan 34.78%
Margin Operasi (TTM) 49.69%
EPS Cair (TTM) 3.31
Pertumbuhan Hasil Suku Tahunan (YOY) 30.10%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 28.50%
Jumlah Hutang/Ekuiti (D/E MRQ) 71.64%
Nisbah Semasa (MRQ) 0.740
Aliran Tunai Operasi (OCF TTM) 120.97 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 61.99 B
Pulangan Atas Aset (ROA TTM) 22.41%
Pulangan Atas Ekuiti (ROE TTM) 80.77%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menaik
Drug Manufacturers - General (Global) Menaik Menaik
Stok Novo Nordisk A/S Bercampur Menaik

AISkor Stockmoo

0.5
Konsensus Penganalisis 2.0
Aktiviti Orang Dalam NA
Volatiliti Harga 5.0
Purata Bergerak Teknikal -2.5
Osilator Teknikal -2.5
Purata 0.50

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
NVO 295 B 2.40% 20.51 16.26
LLY 735 B 0.66% 69.93 52.04
MRK 225 B 3.50% 13.24 4.78
NVS 222 B 3.54% 19.18 4.89
JNJ 385 B 3.10% 27.60 5.50
ABBV 367 B 3.03% 87.24 109.22

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Growth
% Dimiliki oleh Institusi 10.25%

Pemilikan

Nama Tarikh Syer Dipegang
Everett Harris & Co /Ca/ 31 Dec 2024 6,453,089
174.45174.45131.10131.1087.7587.7544.4044.401.051.05Harga Sasaran MedianQ4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
03 Apr 2025 Pengumuman Novo Nordisk announces changes in Executive Management
02 Apr 2025 Pengumuman Lexaria's Human GLP-1 Study #5 Begins Dosing
29 Mar 2025 CNBC Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
29 Mar 2025 Pengumuman Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
29 Mar 2025 Pengumuman Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
27 Mar 2025 Pengumuman Resolutions from the Annual General Meeting of Novo Nordisk A/S
24 Mar 2025 CNBC Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
24 Mar 2025 Pengumuman The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
24 Mar 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
24 Mar 2025 Pengumuman Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
22 Mar 2025 CNBC Zepbound copycats remain online despite FDA ban
20 Mar 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
18 Mar 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
17 Mar 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
13 Mar 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
11 Mar 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
10 Mar 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
10 Mar 2025 Pengumuman Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
06 Mar 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
05 Mar 2025 Pengumuman Novo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients
05 Mar 2025 CNBC Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
05 Mar 2025 CNBC Amgen starts two critical late-stage trials for weight loss drug MariTide
04 Mar 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
03 Mar 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
27 Feb 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
27 Feb 2025 Pengumuman Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
26 Feb 2025 CNBC Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
25 Feb 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
24 Feb 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
21 Feb 2025 CNBC Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
20 Feb 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
18 Feb 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
13 Feb 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
11 Feb 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
10 Feb 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
10 Feb 2025 CNBC Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
07 Feb 2025 Pengumuman Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
06 Feb 2025 Pengumuman Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
06 Feb 2025 Pengumuman Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
06 Feb 2025 CNBC Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
05 Feb 2025 Pengumuman Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
05 Feb 2025 Pengumuman Novo Nordisk files annual report with the SEC
05 Feb 2025 CNBC Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
30 Jan 2025 Pengumuman Lexaria Releases Annual Letter From the CEO
28 Jan 2025 CNBC Food-as-medicine startups hope Kennedy, if confirmed as HHS secretary, will boost their businesses
28 Jan 2025 CNBC FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
27 Jan 2025 Pengumuman Novo Nordisk A/S - share repurchase programme
24 Jan 2025 Pengumuman Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
17 Jan 2025 Pengumuman Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
17 Jan 2025 CNBC Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
14 Jan 2025 CNBC Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
13 Jan 2025 CNBC Eli Lilly CEO expects new weight loss pill to be approved next year
13 Jan 2025 Pengumuman Novo Nordisk A/S - share repurchase programme
13 Jan 2025 CNBC High cost of weight loss drugs drives employers to require nutrition counseling, in boost for startups
09 Jan 2025 CNBC Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
08 Jan 2025 Pengumuman Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
Papar semua
Hasil Dividen (DY TTM) 2.40%
Purata Hasil Dividen 5T 2.48%
Nisbah Pembayaran 43.78%
Jangkaan Pembayaran Dividen Seterusnya Aug 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
31 Mar 2025 05 Feb 2025 08 Apr 2025 1.099206 Tunai
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 Tunai
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 Tunai
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 Tunai
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 Tunai
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 Tunai
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 Tunai
16 Aug 2021 - 25 Aug 2021 0.5502889 Tunai
26 Mar 2021 - 07 Apr 2021 0.922122 Tunai
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 Tunai
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 Tunai
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 Tunai
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 Tunai
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 Tunai
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 Tunai
17 Aug 2017 - 29 Aug 2017 0.33589 Tunai
23 Mar 2017 - 04 Apr 2017 0.479369 Tunai
11 Aug 2016 - 23 Aug 2016 0.331026 Tunai
18 Mar 2016 - 30 Mar 2016 0.69943 Tunai
19 Mar 2015 - 31 Mar 2015 0.532885 Tunai
21 Mar 2014 - 02 Apr 2014 0.606122 Tunai
21 Mar 2013 - 02 Apr 2013 2.264307 Tunai
22 Mar 2012 - 03 Apr 2012 1.831902 Tunai
24 Mar 2011 - 05 Apr 2011 1.357901 Tunai
25 Mar 2010 - 07 Apr 2010 0.978615 Tunai
19 Mar 2009 - 31 Mar 2009 0.781532 Tunai
13 Mar 2008 - 25 Mar 2008 0.678462 Tunai
08 Mar 2007 - 20 Mar 2007 0.891779 Tunai
09 Mar 2006 - 21 Mar 2006 0.691753 Tunai
10 Mar 2005 - 22 Mar 2005 0.61725 Tunai
17 Mar 2004 - 29 Mar 2004 0.52096 Tunai
26 Mar 2003 - 07 Apr 2003 0.37647 Tunai
13 Mar 2002 - 25 Mar 2002 0.2848 Tunai
21 Mar 2001 - 02 Apr 2001 0.5681 Tunai
24 Mar 2000 - 06 Apr 2000 0.4672 Tunai
25 Mar 1999 - 06 Apr 1999 0.4182 Tunai
27 Mar 1998 - 08 Apr 1998 0.3051 Tunai
25 Apr 1997 - 07 May 1997 0.239 Tunai
01 May 1996 - 14 May 1996 0.1806 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.10 1 1.63
2024 1.44 2 1.68
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
Papar semua
85.1085.1078.4878.4871.8571.8565.2265.2258.6058.60Mar 25Mar 25Mar 26Mar 26Mar 27Mar 27Mar 28Mar 28Mar 31Mar 31Apr 1Apr 1Apr 2Apr 2Apr 3Apr 3

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0000.000-2.000-2.000-4.000-4.000-6.000-6.000-8.000-8.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda